Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telmesteine SCHEMBL1425417 | 1.00 | ACE (0.53) | ACEPREPRAB9ATSHRPPM1B | |
| SCHEMBL6706811 | 0.86 | ACE (0.47) | ACEPREPRAB9ATSHRATM | |
| SCHEMBL7769271 | 0.85 | PREP (0.40) | ACEPREPTSHRATMRECQL | |
| SCHEMBL7769272 | 0.85 | GAA (0.42) | ACEPREPTSHRGAA | |
| Telmesteine SCHEMBL7269300 | 0.81 | GSR (0.46) | ACEPREP | |
| Telmesteine SCHEMBL7269301 | 0.81 | GSR (0.46) | ACEPREP | |
| SCHEMBL5494135 | 0.80 | ACE (0.54) | ACEPREPRAB9AATM | |
| SCHEMBL19084116 | 0.79 | ACE (0.55) | ACEPREPTSHR | |
| SCHEMBL6051964 | 0.79 | ACE (0.55) | ACEPREPTSHR | |
| SCHEMBL202300 | 0.78 | ACE (0.48) | ACEPREPATMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2026-05-14 | — | — | US | claimed |
| US-20240216353-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-07-04 | — | — | US | claimed |
| US-20210315873-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-10-14 | — | — | US | claimed |
| CN-109248319-A | Contain the pharmaceutical composition for taking charge of smooth class compound and aspirin | 郜建敏 | 2019-01-22 | — | — | CN | claimed |
| CN-107157976-A | Application of the compound of thioether acids structure in medicament for resisting platelet aggregation is prepared | 北京北朋科技有限公司 | 2017-09-15 | — | — | CN | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | UNIVERSITY OF CHICAGO (US) | 2014-06-26 | — | — | US | claimed |
| EP-2637679-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | The University of Chicago (US) | 2013-09-18 | — | — | EP | claimed |
| US-8431601-B2 | Topical compositions comprising telmesteine for treating dermatological disorders | SINCLAIR PHARMACEUTICALS LTD. (GB) | 2013-04-30 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-20060247183-A1 | Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye | SINCLAIR PHARMACEUTICALS LTD. (GB) | 2006-11-02 | — | — | US | claimed |
| EP-1670464-A1 | TOPICAL COMPOSITIONS COMPRISING TELMESTEINE FOR TREATING DERMATOLOGICAL DISORDERS | Sinclair Pharmaceuticals Limited (GB) | 2006-06-21 | — | — | EP | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20050143324-A1 | Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye | SINCLAIR PHARMACEUTICALS, LTD. | 2005-06-30 | — | — | US | claimed |
| WO-2005037275-A1 | TOPICAL COMPOSITIONS COMPRISING TELMESTEINE FOR TREATING DERMATOLOGICAL DISORDERS | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2005-04-28 | — | — | WO | claimed |
| EP-1494692-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING PROANTHOCYANIDINS FOR THE TREATMENT OF DERMATITIS | Sinclair Pharmaceuticals Limited (GB) | 2005-01-12 | — | — | EP | claimed |
| WO-2003084553-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING PROANTHOCYANIDINS FOR THE TREATMENT OF DERMATITIS | SINCLAIR PHARMACEUTICALS LIMITED (GB) | 2003-10-16 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130899-A1 | METHOD OF TREATMENT FOR PREVENTION OF GLUCOCORTICOID TOXICITY AND/OR ENHANCEMENT OF MUSCLE REGENERATION VIA NEUTROPHIL ELASTASE INHIBITION | SERPINB1, ELANE, CELA1 | ACE 151/4885PREP 269/4885RAB9A 2398/4885 |
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | ADAM10, ADAM8, ADAM17 | ACE 93/4885PREP 41/4885RAB9A 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.